For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

An effective, targeted combination that provides unprecedented results

Treatment-naïve patients with BRAF V600+ NSCLC: Maximum reduction in target lesions (investigator assessed)1

 Tafinlar® (dabrafenib) and Mekinist® (trametinib) efficacy in treatment-naïve patients.

NE patients did not have a follow-up scan required for confirmation. The dotted line at –30 represents the RECIST 1.1 definition for partial response.

Adapted from Planchard et al.

Previously treated patients with BRAF V600+ NSCLC: Maximum reduction in target lesions (investigator-assessed)2

 Tafinlar® (dabrafenib) and Mekinist® (trametinib) efficacy in previously treated patients.

 

NE patients did not have a follow-up scan required for confirmation. The dotted line at –30 represents the RECIST 1.1 definition for partial response.

Adapted from Planchard et al.

DCR=CR + PR + SD.

CR, complete response; DCR, disease control rate; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

References: 1. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial [published online September 8, 2017]. Lancet Oncol. doi:10.1016/S1470-2045(17)30679-4. 2. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984-993.